AOS to face competition
Wednesday, 25 June, 2008
Advanced Ocular Systems (ASX: AOS) will have to contend with a new competitor for its Triesence injectable triamcinolone acetonide anti-inflammatory, company directors warned the market yesterday.
The new product, known as Trivaris, is manufactured by Allergan. The FDA recently approved the drug for sale.
It will be in direct competition with Triesence, which was developed by AOS and is sold under license through Alcon.
The potential effect on the company's royalties revenues is currently unclear, AOS said.
Injectable triamcinolone acetonide is mainly used to treat inflammation of the eyes and other similar ocular diseases and disorders.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
